Targeting Pathological Neurotransmission Dynamics Through de novo Regulatory Modulation to Suppress Glioma Progression
ISEF · 2026 Biochemistry
Overview
Glioma is an aggressive, life-threatening form of brain cancer with poor clinical outcomes. Despite decades of research, tumor-intrinsic mutations cannot explain disease progression alone. Current understanding and effective therapies are limited by the complex nature of the brain's surrounding microenvironment. This project aims to investigate neurotransmission dynamics as an upstream regulator of glioma progression and allow for efficient therapeutic strategy development. Synaptic vesicle fusion, driving timed release of transmitters, is tightly regulated by soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complexes. Native mass spectrometry was used to analyze the stoichiometry and conformation of SNARE regulatory assemblies under glioma conditions, revealing a novel redistribution toward fusion-permissive conformations with relative abundance increases of 1.4x–2.1 (p < 0.01). Further analysis of neuronal proteomic datasets demonstrated elevated tumor-supportive signaling through a 1.5x increase in neuroligin-3 under conditions of elevated synaptic activity (p < 0.05). Next, high-performance modeling found these distributions changed transmission kinetics from synchronous to sustained release. Finally, to explore therapeutic intervention, the design of de novo modulation targeting SNARE dysregulation revealed a binding affinity of -10.2 kcal/mol. Molecular dynamics simulations confirmed stability with an RMSD below 2.0 Å over 50–100 ns and a radius of gyration stabilized at ~2.9–3.0 nm. Overall, this project's findings connect glioma progression to synaptic dysregulation, directing effective therapeutic intervention.
Competition history
- ISEF 2026
Resources
Related projects
ISEF · 2026
Protein Assassins: Screening for Improved Degraders to Reverse Tumor Immortality
ISEF · 2025
Molecular Arsonists: Degrading Oncogenic Transcription Factors to Reverse Tumor Cell Immortality
CWSF · 2026
Brain-Penetrating Bioconjugate M13-CTX-PEP-1 for Targeted Glioblastoma Therapy In Silico
ISEF · 2020
Analyzing the Effect of Neuropilin 1 Knockdown on Conventional Chemotherapy in GBM
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair